Citadel Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.7M | Sell |
1,018,743
-280,159
| -22% | -$2.18M | ﹤0.01% | 3305 |
|
|
2025
Q4 | $10.1M | Sell |
1,298,902
-60,980
| -4% | -$441K | ﹤0.01% | 3242 |
|
|
2025
Q3 | $10.3M | Sell |
1,359,882
-1,197,550
| -47% | -$9.97M | ﹤0.01% | 3225 |
|
|
2025
Q2 | $22.9M | Buy |
2,557,432
+1,983,243
| +345% | +$18.5M | ﹤0.01% | 1992 |
|
|
2025
Q1 | $4.31M | Buy |
574,189
+315,644
| +122% | +$2.55M | ﹤0.01% | 4126 |
|
|
2024
Q4 | $1.94M | Sell |
258,545
-20,598
| -7% | -$156K | ﹤0.01% | 5690 |
|
|
2024
Q3 | $2.12M | Sell |
279,143
-38,836
| -12% | -$295K | ﹤0.01% | 5423 |
|
|
2024
Q2 | $1.97M | Buy |
317,979
+157,894
| +99% | +$871K | ﹤0.01% | 5346 |
|
|
2024
Q1 | $813K | Sell |
160,085
-209,551
| -57% | -$1.18M | ﹤0.01% | 7372 |
|
|
2023
Q4 | $2.21M | Sell |
369,636
-1,011,234
| -73% | -$5.86M | ﹤0.01% | 5183 |
|
|
2023
Q3 | $9.78M | Buy |
1,380,870
+321,309
| +30% | +$2.31M | ﹤0.01% | 2712 |
|
|
2023
Q2 | $7.46M | Buy |
1,059,561
+154,491
| +17% | +$1.24M | ﹤0.01% | 3067 |
|
|
2023
Q1 | $7.55M | Buy |
905,070
+846,651
| +1,449% | +$8.15M | ﹤0.01% | 3174 |
|
|
2022
Q4 | $671K | Sell |
58,419
-912,896
| -94% | -$11.4M | ﹤0.01% | 7633 |
|
|
2022
Q3 | $12.2M | Buy |
971,315
+428,854
| +79% | +$5.52M | ﹤0.01% | 2468 |
|
|
2022
Q2 | $5.74M | Buy |
542,461
+93,305
| +21% | +$962K | ﹤0.01% | 3541 |
|
|
2022
Q1 | $7.3M | Buy |
449,156
+50,783
| +13% | +$815K | ﹤0.01% | 3473 |
|
|
2021
Q4 | $5.52M | Sell |
398,373
-557,481
| -58% | -$7.38M | ﹤0.01% | 4127 |
|
|
2021
Q3 | $13.7M | Sell |
955,854
-77,449
| -7% | -$1.22M | ﹤0.01% | 2562 |
|
|
2021
Q2 | $16.3M | Buy |
1,033,303
+225,691
| +28% | +$3.07M | ﹤0.01% | 2347 |
|
|
2021
Q1 | $8.21M | Sell |
807,612
-5,688,305
| -88% | -$58.7M | ﹤0.01% | 3282 |
|
|
2020
Q4 | $48.4M | Sell |
6,495,917
-2,168,814
| -25% | -$11.2M | 0.01% | 966 |
|
|
2020
Q3 | $29.8M | Buy |
8,664,731
+179,023
| +2% | +$767K | 0.01% | 1233 |
|
|
2020
Q2 | $40.4M | Buy |
8,485,708
+2,376,174
| +39% | +$9.49M | 0.01% | 943 |
|
|
2020
Q1 | $12.2M | Buy |
6,109,534
+153,555
| +3% | +$423K | 0.01% | 1660 |
|
|
2019
Q4 | $20.5M | Buy |
5,955,979
+2,122,508
| +55% | +$5.34M | 0.01% | 1451 |
|
|
2019
Q3 | $11M | Buy |
3,833,471
+340,873
| +10% | +$1.06M | 0.01% | 2110 |
|
|
2019
Q2 | $13.2M | Buy |
3,492,598
+1,283,723
| +58% | +$7.72M | 0.01% | 1845 |
|
|
2019
Q1 | $18M | Buy |
2,208,875
+1,488,671
| +207% | +$12.7M | 0.01% | 1435 |
|
|
2018
Q4 | $5.81M | Buy |
720,204
+665,917
| +1,227% | +$5.18M | ﹤0.01% | 2573 |
|
|
2018
Q3 | $415K | Sell |
54,287
-12,402
| -19% | -$83.3K | ﹤0.01% | 6999 |
|
|
2018
Q2 | $382K | Sell |
66,689
-395,390
| -86% | -$2.18M | ﹤0.01% | 6809 |
|
|
2018
Q1 | $2.2M | Buy |
+462,079
| New | +$2.37M | ﹤0.01% | 3579 |
|
|
2017
Q4 | – | Sell |
-1,395,547
| Closed | -$6.76M | – | 7953 |
|
|
2017
Q3 | $7.31M | Buy |
1,395,547
+1,239,689
| +795% | +$6.35M | 0.01% | 1902 |
|
|
2017
Q2 | $866K | Buy |
155,858
+21,333
| +16% | +$130K | ﹤0.01% | 4289 |
|
|
2017
Q1 | $1.13M | Buy |
134,525
+23,671
| +21% | +$165K | ﹤0.01% | 3828 |
|
|
2016
Q4 | $702K | Buy |
+110,854
| New | +$577K | ﹤0.01% | 4371 |
|
|
2015
Q4 | – | Sell |
-143,954
| Closed | -$1.43M | – | 8717 |
|
|
2015
Q3 | $1.64M | Sell |
143,954
-650,637
| -82% | -$8.68M | ﹤0.01% | 3196 |
|
|
2015
Q2 | $11.9M | Buy |
794,591
+757,207
| +2,025% | +$8.61M | 0.01% | 1355 |
|
|
2015
Q1 | $338K | Buy |
+37,384
| New | +$387K | ﹤0.01% | 5479 |
|
|
2014
Q4 | – | Sell |
-93,409
| Closed | -$1.03M | – | 8475 |
|
|
2014
Q3 | $914K | Sell |
93,409
-2,659
| -3% | -$32.6K | ﹤0.01% | 3820 |
|
|
2014
Q2 | $1.22M | Buy |
96,068
+85,247
| +788% | +$829K | ﹤0.01% | 3240 |
|
|
2014
Q1 | $114K | Sell |
10,821
-31,982
| -75% | -$341K | ﹤0.01% | 6073 |
|
|
2013
Q4 | $325K | Buy |
+42,803
| New | +$271K | ﹤0.01% | 4518 |
|
|
2013
Q3 | – | Sell |
-29,974
| Closed | -$152K | – | 6726 |
|
|
2013
Q2 | $46K | Buy |
+29,974
| New | +$51.7K | ﹤0.01% | 5706 |
|
Other funds holding BCRX
RCM
DM
VPM
VCM
TCM
PA
VPC
Citadel Advisors's BCRX Position: Q1 2026 in Review
Citadel Advisors reduced its BioCryst Pharmaceuticals (BCRX) stake by 22% in Q1 2026, selling an estimated $2.18M and leaving 1,018,743 shares worth $9.7M. The position accounts for ﹤0.01% of the portfolio, ranked #3305.
Citadel Advisors first reported a position in BCRX in Q2 2013 and has held it in 45 quarters since. The position peaked at $48.4M in Q4 2020. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.
- Citadel Advisors held 1,018,743 shares of BioCryst Pharmaceuticals worth $9.7M as of Q1 2026.
- Citadel Advisors sold 280,159 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $2.18M.
- BioCryst Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3305 holding.
- Citadel Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
- Citadel Advisors's BioCryst Pharmaceuticals position peaked at $48.4M in Q4 2020.
- 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.